2.71
-4.24%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About HeartSciences
From its filings with the US Securities and Exchange Commission
HeartSciences is based in Southlake, Texas and is incorporated in Texas. Its shares trade on Nasdaq under the ticker HSCS. The SEC classifies its business as finance services. In the fiscal year to 30 April 2026, it reported revenue of $4,319 and a net loss of $9.1m.
We are a healthcare information technology company focused on advancing electrocardiography (“ECG” or “EKG”) through the integration of artificial intelligence (“AI”). Our first commercial product is MyoVista Insights™, a cloud-native, vendor- and device-agnostic ECG management platform designed to modernize ECG workflows and enable scalable deployment of AI-ECG capabilities across healthcare systems.
MyoVista Insights™ is classified as a Medical Device Data System (“MDDS”) and is exempt from the FDA 510(k) requirements. The platform is designed to streamline ECG study organization, enhance waveform analysis, and simplify clinical workflows, enabling more efficient interpretation, storage, and management of ECG data. It is also designed to host AI-ECG algorithms from multiple vendors and integrate them directly into clinical workflows, providing a flexible and extensible foundation for the adoption of AI in ECG.
Following its early adopter launch in 2025, we have implemented phased enhancements to MyoVista Insights™. In March 2026, we released a significant version upgrade for broader deployment across cardiology and healthcare IT environments. This release included mobile device access, enhanced reporting capabilities, and expanded interoperability designed to support integration across large health systems and enterprise environments.
Quoted from its 10-K, filed 23 Jul 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 15 Jun 2022
- Employees
- 12
- Website
- heartsciences.com ↗
- Head office
- 550 RESERVE ST, SUITE 360, SOUTHLAKE, TX, 76092
- Incorporated in
- TX
- Classification
- Finance Services
- Filer status
- <br>Emerging growth company
Leadership
Pay as last reported
- Mr. Andrew SimpsonChairman of the Board, President, Chief Executive Officer, since 2012$300,000
- Ms. Danielle WatsonChief Financial Officer, Treasurer$179,317
- Mr. Mark HilzChief Operating Officer, Secretary, Director, since 2013$300,000
- Mr. Bruce BentIndependent Director$60,000
- Mr. Brian SzymczakIndependent Director$57,500
- Mr. David WellsIndependent Director$57,500
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- MyoVista provides diagnostic information on cardiac dysfunction using AI-based technology.
- HeartSciences Inc employs 12 full-time staff members in Southlake, Texas.
- The company applies innovative AI to electrocardiogram devices for clinical use.
Weaknesses
- HeartSciences Inc has only 12 employees, limiting its operational capacity.
- The firm relies on outsourced production facilities for manufacturing its devices.
- MyoVista is the company's first device, indicating a narrow product portfolio.
Opportunities
- HeartSciences Inc can market its device domestically to various hospitals and clinics.
- The firm can expand internationally to reach more medical centers globally.
- AI technology can extend clinical indications for electrocardiograph device usage.
Threats
- HeartSciences Inc went public on 15 June 2022, facing market scrutiny.
- The company is headquartered in Southlake, which may limit talent access.
- MyoVista competes with traditional cardiac imaging methods in clinical settings.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.